Key result
Carvedilol led to greater regression of carotid intima-media thickness compared to metoprolol (49% vs 18%, P<.01) in newly diagnosed hypertensive patients with morning blood pressure peak.
Why the study?
Does carvedilol reduce CIMT and circulating inflammatory markers compared to metoprolol in drug-naive hypertensive patients with morning blood pressure peak?
Population
128 drug-naive hypertensive patients with morning blood pressure peak (MP+)
Comparison
Carvedilol vs Metoprolol
Design
RCT, randomly assigned
Follow-up
12 months
Authors
Loading...
Favors carvedilol over metoprolol for morning-peaking hypertension; extends beta-blocker differentiation on vascular outcomes in RCTs.
RCT (n=324)
Randomized
Does carvedilol reduce CIMT and circulating inflammatory markers compared to metoprolol in drug-naive hypertensive patients with morning blood pressure peak?
Absolute Event Rate: 49% vs 18%
p-value: p=<.01
Carvedilol is more effective than metoprolol in reducing morning blood pressure peak, carotid atherosclerosis, and inflammatory markers in newly diagnosed hypertensive patients.
Marfella et al. (2005) conducted an RCT in Hypertension with morning blood pressure peak (n=324). Carvedilol vs. Metoprolol was evaluated on Change in CIMT and circulating inflammatory markers at 12 months (p=<.01). Carvedilol led to greater regression of carotid intima-media thickness compared to metoprolol (49% vs 18%, P<.01) in newly diagnosed hypertensive patients with morning blood pressure peak.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: